<!DOCTYPE html><html><head><title> Pacifica Code Section 58-85-S102 </title><link rel="stylesheet" href="../../assets/style.css"/></head><body>
<b><i>
                      Effective 12/3/2018</i></b>
<br>
<b>58-85-102.&nbsp;
          </b><b>Definitions.</b>
<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As used in this chapter:<a id="58-85-102(1)" name="58-85-102(1)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(1)</td><td style="width:99%">
"Eligible patient" means an individual who has been diagnosed with a terminal illness by a physician.</td>
</tr>
</tbody></table>
<a id="58-85-102(2)" name="58-85-102(2)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(2)</td><td style="width:99%">
"Insurer" means the same as that term is defined in Section <a href="../../Title31A/Chapter1/31A-1-S301.html?v=C31A-1-S301_2020051220200512">31A-1-301</a>.</td>
</tr>
</tbody></table>
<a id="58-85-102(3)" name="58-85-102(3)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(3)</td><td style="width:99%">
"Investigational device" means a device that:
<a id="58-85-102(3)(a)" name="58-85-102(3)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
meets the definition of "investigational device" in 21 C.F.R. Sec. 812.3; and</td>
</tr>
</tbody></table>
<a id="58-85-102(3)(b)" name="58-85-102(3)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
has successfully completed the United States Food and Drug Administration Phase 1 testing for an investigational device described in 21 C.F.R. Part 812.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="58-85-102(4)" name="58-85-102(4)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(4)</td><td style="width:99%">
"Investigational drug" means a drug that:
<a id="58-85-102(4)(a)" name="58-85-102(4)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
meets the definition of "investigational new drug" in 21 C.F.R. Sec. 312.3; and</td>
</tr>
</tbody></table>
<a id="58-85-102(4)(b)" name="58-85-102(4)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
has successfully completed the United States Food and Drug Administration Phase 1 testing for an investigational new drug described in 21 C.F.R. Part 312.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="58-85-102(5)" name="58-85-102(5)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(5)</td><td style="width:99%">
"Medicinal dosage form" means the same as that term is defined in Section <a href="../../Title58/Chapter37/58-37-S3.6.html?v=C58-37-S3.6_2019020220190701">58-37-3.6</a>.</td>
</tr>
</tbody></table>
<a id="58-85-102(6)" name="58-85-102(6)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(6)</td><td style="width:99%">
"Physician" means an individual who is licensed under:
<a id="58-85-102(6)(a)" name="58-85-102(6)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%"><a href="../../Title58/Chapter67/58-67.html?v=C58-67_1800010118000101">Title 58, Chapter 67, Utah Medical Practice Act</a>; or</td>
</tr>
</tbody></table>
<a id="58-85-102(6)(b)" name="58-85-102(6)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%"><a href="../../Title58/Chapter68/58-68.html?v=C58-68_1800010118000101">Title 58, Chapter 68, Utah Osteopathic Medical Practice Act</a>.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="58-85-102(7)" name="58-85-102(7)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(7)</td><td style="width:99%">
"Terminal illness" means a condition of a patient that:
<a id="58-85-102(7)(a)" name="58-85-102(7)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
as determined by a physician:<a id="58-85-102(7)(a)(i)" name="58-85-102(7)(a)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
is likely to pose a greater risk to the patient than the risk posed to the patient by treatment with an investigational drug or investigational device; and</td>
</tr>
</tbody></table>
<a id="58-85-102(7)(a)(ii)" name="58-85-102(7)(a)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
will inevitably lead to the patient's death; and</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="58-85-102(7)(b)" name="58-85-102(7)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
presents the patient, after the patient has explored conventional therapy options, with no treatment option that is satisfactory or comparable to treatment with an investigational drug or device.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<br>
<br>Amended by Chapter <a href="http://le.utah.gov/UtahCode/ChapterLookup.jsp?chap=1&amp;sess=2018S3">1</a>, 2018 Special Session 3<br>
</body></html>